Sungkyunkwan University · 医学
Professor Dong Hyun Sinn's research lab specializes in hepatology and liver disease management, with a strong focus on hepatocellular carcinoma (HCC) risk prediction, antiviral therapy optimization in chronic hepatitis B and C, and multidisciplinary team (MDT) approaches to improve outcomes in liver cirrhosis and HCC. The lab investigates treatment thresholds, risk stratification, and the impact of early antiviral therapy in patients who do not meet conventional criteria, particularly in Asian populations. They also explore comorbidities such as NAFLD and sarcopenia, emphasizing early detection and intervention to improve long-term liver health.
Figures are computed from collected data and may differ slightly.
A certain proportion of Korean patients started therapy with a higher than targeted ribavirin dose, which resulted in more ribavirin dose modifications without definite additional benefit in achieving SVR. Therefore, the ribavirin dosing regimen might need to be reassessed.
Compensated cirrhosis patients with detectable, but low, viral load were not at low risk for HCC, and AVT was associated with lower HCC risk, suggesting that prompt AVT should be considered for these patients.
MDT management was associated with improved overall survival in HCC patients, indicating that MDT management can be a valuable option to improve outcome of HCC patients. This warrants prospective evaluations.
We assessed the incidence of hepatocellular carcinoma (HCC) in those outside of current treatment recommendations and risk factors associated with HCC development. A multi-centre, retrospective cohort of 3624 patients who were monitored without antiviral treatment was analysed. Incident HCC risk according to the Asian Pacific Association for the study of the Liver (APASL), the American Association for the Study of Liver Disease (AASLD) and the European Association for the Study of the Liver (EAS
In this Asian cohort study, the Baveno VI criteria were able to identify who could safely avoid screening endoscopy. The expanded Baveno VI criteria could spare more endoscopies but also could increase the odds of missing a high-risk varix.
Participants with NAFLD were at increased risk of sarcopenia, indicated by faster loss of skeletal muscle mass. Patients with NAFLD may need screening and early intervention to mitigate skeletal muscle mass loss.
The combined use of two non-invasive serum biomarkers (APRI and FIB-4) could stratify HCC risk for chronic HBV-infected patients with LLV.
While gastro-oesophageal reflux disease may be an aggravating factor in patients with globus, it does not appear to be the sole cause of globus symptom.
Open papers in the app to read, cite, and organize with AI.
